

China Focused Company - GNI Group (TSE: 2160) - Potential of F647 (Pirfenidone) in China

<https://marketpublishers.com/r/CAE0ECDFFA2EN.html>

Date: May 2012

Pages: 8

Price: US\$ 140.00 (Single User License)

ID: CAE0ECDFFA2EN

Abstracts

GNI Group (TSE: 2160) company whose major focus is on the Chinese market through Shanghai Genomics (100% ownership), and Beijing Continent (51% ownership). China's market for IPF is GNI's focus and at the current valuation (if convinced about the market size) it could present an investment opportunity. China regulatory approval of F647's manufacturing facility and launch timeline are uncertain, and the report focuses mainly on product's effectiveness, physicians' feedback, the competitive landscape and our estimates of the Chinese market for IPF.

Contents

COMPANIES MENTIONED

GNI Group (TSE: 2160)

I would like to order

Product name: China Focused Company - GNI Group (TSE: 2160) - Potential of F647 (Pirfenidone) in China

Product link: <https://marketpublishers.com/r/CAE0ECDFFA2EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CAE0ECDFFA2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

